Johnson & Johnson reports TREMFYA trial results
- Johnson & Johnson reported that TREMFYA met its primary and major secondary endpoints in the Phase 4 STAR study of axial psoriatic arthritis.
- The study showed improvements in patient-reported disease activity scores, axial symptoms, and MRI-measured sacroiliac-joint inflammation at Week 24.
- Johnson & Johnson said the safety profile remained consistent with TREMFYA’s established profile in psoriatic arthritis, with no new safety signals identified.
Johnson & Johnson (NYSE:JNJ) reported that TREMFYA met its primary and major secondary endpoints in the Phase 4 STAR study evaluating adults with active psoriatic arthritis and MRI-confirmed axial inflammation.
The randomized, double-blind, placebo-controlled study enrolled 411 biologic-naïve adults and assessed TREMFYA’s impact on axial symptoms during a 24-week placebo-controlled period followed by 24 weeks of active treatment.
At Week 24, TREMFYA met the primary endpoint by improving BASDAI scores compared with placebo, while major secondary endpoints showed reductions in axial symptoms measured by ASDAS-CRP and sacroiliac-joint inflammation measured through MRI.
Johnson & Johnson develops healthcare products across pharmaceuticals, medical technology, and other healthcare areas, including TREMFYA, a treatment used in inflammatory disease conditions.
The company said detailed efficacy and safety results from the STAR study, including MRI findings, will be presented at an upcoming scientific congress.
